The FDA updated the indication and usage section of the Dapagliflozin label on 2026-07-02. This revision adds a new indication: 'To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.' This update significantly expands the therapeutic scope of Dapagliflozin.
Background
Dapagliflozin is an oral medication primarily used for the treatment of type 2 diabetes mellitus. Its previous indications focused on improving glycemic control. This label change signifies an important expansion of its recognized therapeutic benefits, specifically addressing cardiovascular outcomes in a high-risk patient population. The drug is known by several aliases, including Farxiga and Xigduo XR (when combined with metformin).
What this means
This label revision for Dapagliflozin provides clinicians with an expanded therapeutic option for adults with type 2 diabetes mellitus who also have established cardiovascular disease or multiple cardiovascular risk factors. The updated indication specifically allows for its use to reduce the risk of hospitalization for heart failure in this patient group. This change is significant for patient management strategies, enabling healthcare providers to leverage Dapagliflozin's proven cardiovascular benefits to mitigate a serious complication in a vulnerable population, thereby potentially improving patient outcomes and reducing healthcare burden. The inclusion of this indication on the official label reinforces the drug's role in comprehensive diabetes and cardiovascular risk management.
Source
The information regarding this label revision was sourced from the FDA, specifically an update to the Dapagliflozin label, effective 2026-07-02. The full details are available on dailymed.nlm.nih.gov.